Bright Health Group ($BHG) Investor Settlement

Bright Health Group has reached a tentative settlement to resolve investor claims that it misled the market about its post-IPO business and financial prospects.

Outline:

Bright Health went public on June 24, 2021 at $18.00 per share, raising approximately $887 million. The Offering Documents and subsequent statements touted the company's growth, financial alignment model, and ability to manage medical costs, without disclosing that Bright Health was ill-equipped to handle COVID-19-related costs and was experiencing declining premium revenue from a failure to capture risk adjustment on newly added lives. On November 11, 2021, the company disclosed a spike in its medical cost ratio to 103.0% and a $296.7 million GAAP net loss for Q3 2021, sending shares down over 32%. The case has now reached a tentative settlement.

Timeline:

• May 19, 2021: Bright Health filed its Registration Statement (Form S-1) with the SEC in connection with the IPO.

• June 24, 2021: Bright Health's common stock began trading on the NYSE under "BHG" following the IPO at $18.00/share.

• June 25, 2021: Bright Health filed its Prospectus (Form 424B4), completing the Offering Documents.

• August 3, 2021: Bright Health reported Q2 2021 results and held an earnings call touting a stable adjusted medical cost ratio and 275% revenue growth.

• November 11, 2021: Bright Health reported Q3 2021 results, disclosing a medical cost ratio of 103.0% and a GAAP net loss of $296.7 million. The stock price fell 32.33%.

Background:

Bright Health Group is an integrated care delivery company operating through two segments, NeueHealth and Bright HealthCare, offering individual and family, Medicare, and employer health insurance plans alongside a network of primary care clinics.

In its IPO Offering Documents and throughout mid-to-late 2021, Bright Health represented that its "alignment model" was delivering consistent medical cost ratio improvement, that it had over $1.2 billion in 2020 revenue and was on pace for over $4 billion in 2021 revenue, and that it could effectively manage medical costs despite rapid growth.

Investors allege these statements were materially false and misleading because Bright Health had overstated its post-IPO prospects and failed to disclose that it was poorly positioned to absorb COVID-19-related costs and was losing premium revenue due to an inability to capture risk adjustment on newly added members.

The truth allegedly emerged on November 11, 2021, when Bright Health reported a medical cost ratio of 103.0% for Q3 2021 — up sharply from 90.1% a year earlier — along with a GAAP net loss of $296.7 million, more than triple the prior year's loss. Shares fell over 32% in a single day, closing at $4.94, well below the $18.00 IPO price. The case has now reached a tentative settlement.

What Can Investors Expect Now?

Bright Health Group has reached a tentative settlement to resolve investor claims that it misled the market about its post-IPO business and financial prospects.

If you were damaged due to this situation, you can check if you are eligible and get more details in the FAQ section once the settlement is finalized.